- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
Auris Medical Holding is a biotechnology business based in the US. Auris Medical Holding shares (EARS) are listed on the NASDAQ and all prices are listed in US Dollars. Auris Medical Holding employs 8 staff and has a trailing 12-month revenue of around $174,475.
|Latest market close||$2.39|
|52-week range||$0.00 - $0.00|
|50-day moving average||$3.25|
|200-day moving average||$3.41|
|Wall St. target price||$14.95|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.48|
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2023-01-16)||N/A|
|1 month (2022-12-23)||N/A|
|3 months (2022-10-23)||N/A|
|6 months (2022-07-23)||N/A|
|1 year (2022-01-23)||N/A|
|2 years (2021-01-27)||-17.01%|
|3 years (2020-01-27)||67.13%|
|5 years (2018-01-26)||391.26%|
|Gross profit TTM||$174,475|
|Return on assets TTM||-21.99%|
|Return on equity TTM||-71.91%|
|Market capitalisation||$39.2 million|
TTM: trailing 12 months
We're not expecting Auris Medical Holding to pay a dividend over the next 12 months.
Auris Medical Holding's shares were split on a 1:20 basis on 30 April 2019. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Auris Medical Holding shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Auris Medical Holding shares which in turn could have impacted Auris Medical Holding's share price.
Over the last 12 months, Auris Medical Holding's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Auris Medical Holding's is 1.4048. This would suggest that Auris Medical Holding's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Auris Medical Holding Ltd. , a clinical-stage biopharmaceutical company, developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy, and CNS disorders. The company's Phase 3 programs under the development include Keyzilen (AM-101) for the treatment of acute inner ear tinnitus; and Sonsuvi (AM-111) for the treatment of acute inner ear hearing loss. It is also developing AM-125 that is in Phase 2 clinical trial for the intranasal treatment of acute peripheral vertigo; AM-201, which has completed Phase 1b clinical trial for the prevention of antipsychotic induced weight gain and drowsiness; and AM-301, a drug-free nasal spray for protection against airborne viruses and allergens, as well as AM-102 for the tinnitus treatment. The company has a collaboration and license agreement with INSERM; and Xigen S. A. to develop, manufacture, and commercialize pharmaceutical products, as well as drug delivery devices and formulations for local administration of therapeutic substances to the inner ear for the treatment of ear disorders.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.